Skip to main
  1. Stocks
  2. West Pharmaceutical Services
  3. Forecast
WST

WST Stock Forecast & Price Target

WST Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

West Pharmaceutical Servs is well positioned by durable, broad-based demand for high-value products, with HVP components up 20% organically and reaching 53% of Q3 revenue, while GLP-1 HVP components grew well into the 30s% range and remained just under 12% of revenue. The company’s outlook is further supported by management’s confidence in Annex-1 upgrades contributing about 200 bps to annual organic growth through the end of the decade, plus a broad conversion runway across injectable biologics and a large international and U.S. opportunity set. Strong execution also shows up in Q3’s 39.7% gross margin and 25.3% adjusted operating margin, and a multiyear productivity plan, automation, and capacity optimization should help translate mix shift into stronger earnings growth.

Bears say

West Pharmaceutical Servs is facing a softer organic growth profile as West Vantage declined 6.6% organically and the CGM program continues to roll off, while the overlap of legacy-program declines and new-program ramps is likely to mute reported segment growth through 2027. Its exposure to GLP-1 demand also looks less durable, since a meaningful shift toward oral formulations could reduce future volume growth for cartridges and auto-injectors that rely on its elastomer components, even though GLP-1s are expected to represent roughly the mid-teens of FY25 revenue. In addition, customer de-stocking, geopolitical and tariff-related supply chain risk, product recall exposure, and the prospect of multiple compression create a weaker fundamental setup if growth or margins fail to reaccelerate.

WST has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of West Pharmaceutical Services and is not a guaranteed prediction by Public.com or investment advice.

WST Analyst Forecast & Price Prediction

Get the latest WST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in WST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About West Pharmaceutical Services (WST) Forecast

Analysts have given WST a Buy based on their latest research and market trends.

According to 9 analysts, WST has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $442.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $442.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

West Pharmaceutical Services (WST)


WST Analyst Forecast & Price Prediction

Get the latest WST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in WST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover WST stock data and trends